A system and a method for identifying a cognate ligand molecules for known proteins.

The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.

Disclosed herein are compositions and methods for tumor treatment involving administering to a subject having a tumor with an amount effective to limit tumor growth or metastasis of an ephrin B1 inhibitor, or a pharmaceutically acceptable salt thereof; and/or an inhibitor of tumor exosomal release, or a pharmaceutically acceptable salt thereof.

The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.

Embodiments disclosed herein relate to methods for prolonging or regulating aspects of a subject's life or immunizing a subject. In particular, methods are provided for increasing or regulating longevity, survival time, life span, and health span comprising, administering to a subject in need of treatment an effective amount of at least one Cdc42-specific inhibitor. Additionally, methods are provided for immunizing a subject comprising, administering to a subject in need of immunization an effective amount of at least one Cdc42-specific inhibitor and administering to said subject one or more immunization dosages. Methods are described that further comprise identifying a subject as one that will benefit from increased longevity, increased survival time, increased life span, increased health span, or immunization. The subject is identified on the basis of the subject's age, the subject's present medical condition, the subject's present medical treatment, or the subject's Cdc42 activity.

The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 1 4-3-3ξ. In a related aspect, the present invention also provides a means of monitoring a patient diagnosed with a neuropsychiatric disorder, such as schizophrenia, by screening for changes to functional levels of protein 14-3-3 ξ. This may be useful, for example, in the context of evaluating the effectiveness of a prophylactic or therapeutic treatment regime or otherwise monitoring the impact of physiological or metabolic changes which may occur in a patient. The method of the present invention is useful in a wide range of applications including, inter alia, providing a means of identifying mammals susceptible to the onset of a neuropsychiatric condition, such as a condition characterized by one or more symptoms of schizophrenia, thereby enabling the implementation of prophylactic or early therapeutic intervention in an effort to either minimize or prevent the onset of the condition. It also provides a means of confirming diagnoses which would otherwise be based solely on an assessment of positive and negative symptoms.

The present invention is related to agonist of adiponectin receptor 1 (AdipoR1) and/or adiponectin receptor 2 (AdipoR2) for the treatment and/or prevention of polycystic ovary syndrome (PCOS).

Methods for treating depression in, and decreasing a dose of ketamine given to, a subject in need thereof, comprising, administering a CaMKII inhibitor are provided.

The present disclosure relates to methods, compositions and products for treating pain, and/or pain related symptoms, associated with dysmenorrhea in a subject. In certain embodiments, the present disclosure provides a method of treating pain, and/or pain related symptoms, associated with dysmenorrhea in a subject, the method comprising intrauterine and/or vaginal administration to the subject of an effective amount of an agent that reduces activation of the innate immune system and thereby treating the pain and/or the pain related symptoms in the subject. Other embodiments are also disclosed.